Disease severity and therapy as predictors of cardiovascular risk in psoriasis: A population-based cohort study

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 3, 2012, Pages 336-343

  Maradit Kremers, H ^a   Icen, M ^a   Ernste, F C ^a   Dierkhising, R A ^a   McEvoy, M T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; HYDROXYUREA; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PSORALEN; RETINOID; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COHORT ANALYSIS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OBESITY; OUTCOMES RESEARCH; PHOTOTHERAPY; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSORIASIS; RISK FACTOR; SYSTEMIC THERAPY;

ADULT; BIOLOGICAL AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84857252866     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04071.x     Document Type: Article

References (46)

1. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med 1999; 340: 115-126. (Pubitemid 29054847)
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998. (Pubitemid 35416635)
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
4. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
5. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010; 130: 919-922.
6. Stern RS. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.
7. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-475. (Pubitemid 9048948)
8. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304. (Pubitemid 16014779)
9. Henseler T, Christophers E. Disease concomitance in psoriasis [see comment]. J Am Acad Dermatol 1995; 32: 982-986.
10. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis [see comment]. Arch Dermatol 1999; 135: 1490-1493.
11. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230. (Pubitemid 38461682)
12. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741. (Pubitemid 44547793)
13. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
14. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-1315.
15. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
16. Melton L. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 266-274. (Pubitemid 126784042)
17. Maradit Kremers H, Crowson CS, Gabriel SE. Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases. Rheum Dis Clin North Am 2004; 30: 819-834. (Pubitemid 39361475)
18. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60: 394-401.
19. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of casecohort designs. J Clin Epidemiol 1999; 52: 1165-1172.
20. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673. (Pubitemid 44205029)
21. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 1996; 49: 223-233. (Pubitemid 26123934)
22. Roger VL, Killian J, Henkel M, et al. Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol 2002; 55: 593-601. (Pubitemid 34621503)
23. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (4 Suppl. A): 6A-13A. (Pubitemid 23285789)
24. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
25. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571.
26. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553. (Pubitemid 28319935)
27. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-1867.
28. Langholz B, Jiao J. Computational methods for case-cohort studies. Comput Stat and Data Anal 2007; 51: 3737-3748. (Pubitemid 46509540)
29. Grambsch PM, Therneau TM. Modeling Survival Data: Extending the Cox Model. Vol Chapter 3: Springer-Verlag, New York, 2000.
30. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models based on Counting Processes. Springer-Verlag, New York, 1993.
31. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. JASA 1989; 84: 1074-1078.
32. de Jager ME, de Jong EM, Meeuwis KA, van de Kerkhof PC, Seyger MM. No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. J Eur Acad Dermatol Venereol 2010; 24: 1333-1339.
33. Rzany B, Naldi L, Schafer T, Stern R, Williams H. The diagnosis of psoriasis: diagnostic criteria [comment]. Br J Dermatol 1998; 138: 917. (Pubitemid 28231550)
34. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? facts and controversies. Clin Dermatol 2010; 28: 67-72.
35. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010; 130: 933-943.
36. Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 2-9.
37. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
38. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-1006.
39. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276. (Pubitemid 46095954)
40. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009; 218: 110-113.
41. El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2010; 24: 661-666.
42. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-1135.
43. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009; 61: 233-239.
44. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
45. Boehncke S, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2010. Dec 18 [Epub ahead of print]
46. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011. [Epub ahead of print].